Massive global study tracks new hives drug in everyday patients
NCT ID NCT07358364
Summary
This study aims to see how well a new drug called remibrutinib works for controlling chronic hives in real-world medical settings. It will follow over 3,000 adults whose doctors have already decided to either increase their current allergy medicine or switch them to remibrutinib. The main goal is to collect information on how effectively the drug controls symptoms and its safety over a two-year period, outside of a controlled clinical trial.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Cleaver Dermatology
RECRUITINGKirksville, Missouri, 63501, United States
Conditions
Explore the condition pages connected to this study.